Heterochiral β-Peptide Polymers Combating Multidrug-Resistant Cancers Effectively without Inducing Drug Resistance

Area of Science:

• Biochemistry
• Materials Science
• Oncology

Background:

• Multidrug resistance (MDR) in cancer chemotherapy is a significant challenge, leading to treatment failure.
• Existing anticancer agents often face limitations due to acquired drug resistance.
• There is a critical need for novel anticancer drugs that can overcome MDR.

Purpose of the Study:

• To design and develop novel heterochiral β-peptide polymers as synthetic mimics of host defense peptides.
• To evaluate the efficacy of these β-peptide polymers against multidrug-resistant cancers.
• To assess the in vivo performance and biocompatibility of the optimal β-peptide polymer.

Main Methods:

• Rational design of heterochiral β-peptide polymers.
• Anticancer activity screening against multidrug-resistant cancer cell lines.
• In vivo studies on tumor growth, metastasis, and biocompatibility in animal models.
• Assessment of stability against proteolysis and scalability of synthesis.

Main Results:

• The optimal β-peptide polymer demonstrated potent and broad-spectrum anticancer activity against MDR cancer cells.
• The polymer's membrane-damaging mechanism confers insusceptibility to drug resistance.
• In vivo studies showed significant inhibition of tumor growth, metastasis, and circulating tumor cell seeding.
• The polymer exhibited excellent biocompatibility and superior stability against proteolysis compared to natural anticancer peptides.

Conclusions:

• Heterochiral β-peptide polymers represent a promising new class of anticancer agents effective against MDR cancers.
• These polymers offer advantages over traditional peptides, including enhanced stability, scalability, and cost-effectiveness.
• The findings suggest a viable strategy for developing next-generation anticancer therapies to combat drug resistance.